Hellow guys, Welcome to my website, and you are watching Iterion Therapeutics - Tegavivint Phase 2 Clinical Trial. and this vIdeo is uploaded by HPR at 2020-10-19T18:01:05-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | Iterion Therapeutics - Tegavivint Phase 2 Clinical Trial |
| Video Uploader | Video From HPR |
| Upload Date | This Video Uploaded At 20-10-2020 01:01:05 |
| Video Discription | Dr. Rahul Aras, CEO of Iterion Therapeutics, a clinical stage biotechnology company developing novel cancer therapeutics discusses the company's lead product, Tegavivint, a unique nuclear β-catenin inhibitor, which is currently advancing to a Phase 2 clinical trial in patients with progressive desmoid tumors. The company will also pursue additional clinical programs in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers this year and in 2021. #IterionTherapeutics #Tegavivint Visit our website www.healtprofessionalradio.com.au Follow us on our social media channels Facebook: https://www.facebook.com/hprfm/ Twitter: https://twitter.com/HealthProRadio Google+: https://plus.google.com/+HealthProfes... Pinterest: https://www.pinterest.com/HealthProRa... Linkedin: https://www.linkedin.com/company/heal... Instagram: https://www.instagram.com/healthprofe... Subscribe to our podcast channels Soundcloud: https://soundcloud.com/healthprofessi... Itunes: https://itunes.apple.com/nz/podcast/h... Support us on Patreon https://www.patreon.com/HPR |
| Category | Science & Technology |
| Tags | health care | health professionals | health professional radio | health radio | health podcast | health radio usa | health radio australia | health radio uk | doctors | nurses | medical technology | health care study | health care research | health care tips | health care system | health care provider | health care channel | podcast | radio | Iterian Therapeutics | Tegavivint | Dr. Rahul Aras | β-catenin inhibitor | acute myeloid leukemia | non-small cell lung cancer | AML | NSCLC |
